Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × AMG 337 × Clear all
NCT02016534 2017-07-02

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Amgen

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡